FDA inspection
Jiangsu Anbison Pharmaceutical Co., Ltd.: FDA inspection ending Jul 16, 2024
FDA inspection 1246817 · Official Action Indicated (OAI) · Taizhou
Key facts
| Inspection ID | 1246817 |
|---|---|
| Firm | Jiangsu Anbison Pharmaceutical Co., Ltd. |
| FEI number | 3021121841 |
| Address | Building G110, Standard Workshop Phase 5 |
| City | Taizhou |
| Fiscal year | 2024 |
| Inspection end date | Jul 16, 2024 |
| Classification | Official Action Indicated (OAI) |
| Project area | Generic Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data